Webinar series provides expert insights
The challenges of managing patients with lung cancer have been compounded by the novel coronavirus (COVID-19) pandemic.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Oncologists and their patients face complex issues, such as the best setting for care delivery, whether treatments should be delayed to minimize infection risk, and how to differentiate between cancer- and viral infection-related symptoms.
Decision-making is further complicated by the extreme demands that responding to the pandemic has placed on hospital personnel and resources.
“We need to make sure our patients don’t feel they are being pushed aside, that we’re not going to take their treatment and their cancer seriously,” says Nathan Pennell, MD, PhD, Director of Cleveland Clinic Cancer Center’s Lung Cancer Medical Oncology Program. “We know that patients with lung cancer have very serious, life-threatening illnesses, potentially in the same time frame as we’re going to be dealing with this pandemic. I don’t think you can use a guideline to make a blanket recommendation for every patient. You have to take into account the severity of their disease. You really have to individualize (decision-making), both for the patient’s situation and what their risk is, and what the risks and resources are at the place where you’re treating them.”
Dr. Pennell is one of several experts taking part in an ongoing weekly webinar series, “Managing Lung Cancer Patients Through the COVID-19 Pandemic: What to Know,” organized by OncLive, the website for oncology specialists. The first two webinar episodes, each approximately an hour in length, are available for streaming by registering here. The next live episode takes place April 8 at 8 pm EST. Viewers will be able to submit questions.
The topics discussed so far by Dr. Pennell and his fellow panelists — Charu Aggerwal, MD, PhD, of the University of Pennsylvania’s Abamson Cancer Center; H. Jack West, MD, of the City of Hope Comprehensive Cancer Center; and Stephen Liu, MD, of Georgetown University — include:
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust